Advertisement
YOU ARE HERE: LAT HomeCollectionsEnzon Inc
IN THE NEWS

Enzon Inc

FEATURED ARTICLES
BUSINESS
January 23, 2001 | From Bloomberg News
Schering-Plough Corp. and Enzon Inc. have won U.S. Food and Drug Administration approval to sell Peg-Intron, a hepatitis C drug that analysts say could have more than $2 billion in annual sales. The injectable drug is a once-weekly version of Schering-Plough's Intron A, the world's top-selling hepatitis medication, and is considered by analysts to be key to increased sales for Schering-Plough over the next five years.
ARTICLES BY DATE
BUSINESS
January 23, 2001 | From Bloomberg News
Schering-Plough Corp. and Enzon Inc. have won U.S. Food and Drug Administration approval to sell Peg-Intron, a hepatitis C drug that analysts say could have more than $2 billion in annual sales. The injectable drug is a once-weekly version of Schering-Plough's Intron A, the world's top-selling hepatitis medication, and is considered by analysts to be key to increased sales for Schering-Plough over the next five years.
Advertisement
BUSINESS
January 23, 1990
Amgen Inc., a biotechnology company in Thousand Oaks, reached agreement with Enzon Inc. under which Enzon will help improve a new Amgen drug that fights bacterial infection. The Amgen drug, granulocyte colony stimulating factor (G-CSF), stimulates production of white blood cells, the body's main defense against bacterial infection. The drug is expected to be of particular help to cancer patients undergoing chemotherapy, and Amgen is seeking U.S.
BUSINESS
August 5, 1999 | Dow Jones
ICN Pharmaceuticals Inc. shares fell 12% Wednesday amid fears that a hepatitis drug by another company might compete with ICN's treatment. ICN's treatment, combined with Schering-Plough Corp.'s Intron A, is called Rebetron. Analysts said another company, Enzon Inc., is developing, also with Schering-Plough, its own version of Intron A for hepatitis C that might be more effective and require fewer injections. Shares of Costa Mesa-based ICN fell $3.25 to $24.81.
BUSINESS
August 6, 1999 | From Bloomberg News
Shares of ICN Pharmaceuticals Inc. fell 16% Thursday after the Costa Mesa-based company posted second-quarter earnings that fell below analysts' estimates. The drug maker said it had boosted spending to expand its European business. Shares fell $4.06 to $20.75 in trading of 4.7 million, almost 10 times the three-month daily average volume. It was the biggest one-day percentage decline in more than four years. The stock has lost nearly 43% of its value since hitting a 52-week high of $36.
BUSINESS
April 19, 2000 | Reuters, Bloomberg News
Biotech stocks got well Tuesday--for a day, anyway--as investors started bargain hunting after the sector's big slump over the last month. "They were down way too much," said Matthew Geller, analyst at CIBC World Markets. "The fundamentals of the group have improved over the past few months." The Amex biotech index soared 10.2%, outpacing the Nasdaq composite's 7.2% surge. The biotech index had tumbled 49% from its March 7 record high to Monday's close.
NEWS
March 24, 1990 | MARLENE CIMONS, TIMES STAFF WRITER
The Food and Drug Administration on Friday approved a new drug for so-called "Bubble Boy Disease" that will enable many children suffering from the rare genetic disorder to escape their sterile plastic environments and live relatively normal lives. Researchers said that the drug may be the forerunner of others useful for treatment of other incurable genetic disorders. "For the first time, there is a treatment for directly correcting an inherited enzyme deficiency disease," said Dr.
BUSINESS
July 27, 2001 | From Times Wire Services
Schering-Plough Corp. said Thursday that U.S. regulators agreed to let it sell the antiviral drug Rebetol as an individual treatment for the liver disease hepatitis C, a decision long awaited by patients seeking a more effective way to use the medicine. Rebetol capsules, which are made by ICN Pharmaceuticals Inc. in Costa Mesa, have been available only in a combination package with a Schering-Plough injectable interferon drug.
BUSINESS
December 28, 2000 | KAREN FESSLER, BLOOMBERG NEWS
The biotechnology industry will introduce a wave of new drugs next year and advance hundreds of experimental medicines through late-stage trials, adding momentum to a stock sector that was a top performer in 2000. More than 20 new drugs from industry giants including Amgen Inc. and Genentech Inc., and smaller companies such as Enzon Inc. and Coulter Pharmaceutical Inc., may boost enthusiasm for biotech shares overall, analysts said.
BUSINESS
April 29, 2000 | Bloomberg News
Department of Deja Vu: Biotechnology stocks soared Friday amid new hopes that genetic discoveries will lead to breakthrough new products. Though the biotech sector soared at the end of last year and the first part of this year, it has been free-falling since last month amid concerns that the speculative stocks rose too far, too fast. Investors have also been worried that it's too soon to say which companies working in the field will profit from scientific advances.
Los Angeles Times Articles
|